Article Text

PDF

Extended report
Randomised, controlled trial of avocado–soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study
  1. Emmanuel Maheu1,
  2. Christian Cadet2,
  3. Marc Marty3,
  4. Dominique Moyse4,
  5. Isabelle Kerloch5,
  6. Philippe Coste5,
  7. Maxime Dougados6,
  8. Bernard Mazières7,
  9. Tim D Spector8,
  10. Hafid Halhol5,
  11. Jean-Marie Grouin9,
  12. Michel Lequesne10
  1. 1Rheumatology Department, AP-HP, St-Antoine Hospital, Paris, France
  2. 2Rheumatology Centre, Paris, France
  3. 3Rheumatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
  4. 4Department of Statistics, DM Consultant, Angers, France
  5. 5Medical Department, Laboratoires Expanscience, Courbevoie, France
  6. 6Rheumatology B Department, Paris-Descartes University; AP-HP, Cochin Hospital, Paris, France
  7. 7Purpan Hospital, Paul-Sabatier-Toulouse 3, University and Rheumatology Centre, Toulouse, France
  8. 8Twin Research, King's College London, London, UK
  9. 9Department of Biostatistics, Rouen University, Rouen, France
  10. 10Rheumatology Department, Léopold Bellan Hospital, Paris, France
  1. Correspondence to Dr E Maheu, Rheumatology Department, AP-HP, St-Antoine Hospital, 4, Bd Beaumarchais, Paris 75011, France; emaheu{at}wanadoo.fr

Abstract

Objective To assess the ability of avocado–soybean unsaponifiable—Expanscience (ASU-E) to slow radiographic progression in symptomatic hip osteoarthritis (OA).

Methods Prospective, randomised, double blind, parallel group, placebo controlled 3 year trial. Patients with symptomatic (painful ≥1 year, Lequesne Index between 3 and 10) hip OA (American College of Rheumatology criteria) and a minimum joint space width (JSW) of the target hip between 1 and 4 mm on a pelvic radiograph were randomly assigned to 300 mg/day ASU-E or placebo. Standing pelvis, target hip anteroposterior (AP) and oblique views were taken annually. The primary outcome was JSW change at year 3, measured at the narrowest point on pelvic or target hip AP view (manual measure using a 0.1 mm graduated magnifying glass). The full analysis dataset (FAS) included all patients having at least two successive radiographs. An analysis of covariance Mixed Model for Repeated Measurements with Missing at Random (for missing data) was performed to compare adjusted 3 year JSW changes (primary outcome) and the percentages of ‘progressors’ (JSW loss≥0.5 mm) between groups.

Results 399 patients were randomised (345 kept in the FAS), aged 62 (35–84) years, 54% women, mean body mass index 27 (SD 4) kg/m2, mean symptom duration 4 (SD 5) years, 0–100 normalised Lequesne Index 30 (SD 9) and global pain visual analogue scale 37 (SD 23) mm. Mean baseline JSW was 2.8 (0.9) mm. There was no significant difference on mean JSW loss (−0.638 mm vs −0.672 mm, p=0.72, in the ASU-E and placebo groups, respectively) but there were 20% less progressors in the ASU-E than in the placebo group (40% vs 50%, respectively, p=0.040). No difference was observed on clinical outcomes. Safety was excellent.

Conclusions 3 year treatment with ASU-E reduces the percentage of JSW progressors, indicating a potential structure modifying effect in hip OA to be confirmed, and the clinical relevance requires further assessment.

Trial registration number on ClinicalTrial.gov NCT01062737

  • Osteoarthritis
  • Treatment
  • DMARDs (synthetic)

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

View Full Text

Statistics from Altmetric.com

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.